Agios Pharmaceuticals Stock (NASDAQ:AGIO)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$28.88

52W Range

$22.24 - $46.00

50D Avg

$29.28

200D Avg

$31.90

Market Cap

$1.71B

Avg Vol (3M)

$1.08M

Beta

0.59

Div Yield

-

AGIO Company Profile

Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

486

IPO Date

Jul 24, 2013

Website

AGIO Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 25	Dec 24	Dec 23
Product	$54.03M	$36.50M	$26.82M
Royalty	-	-	-

Fiscal year ends in Dec 25 | Currency in USD

AGIO Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	$54.03M	$36.50M	$26.82M
Operating Income	$-472.13M	$-425.74M	$-391.49M
Net Income	$-412.78M	$673.73M	$-352.09M
EBITDA	$-472.13M	$-420.08M	$-384.86M
Basic EPS	$-7.12	$11.86	$-6.33
Diluted EPS	$-7.12	$11.64	$-6.33

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q1 26Apr 29, 26 | 12:00 AM

Q4 25Feb 12, 26 | 12:00 AM

Q3 25Oct 30, 25 | 8:00 AM

Peer Comparison

Ticker	Company
GLPG	Galapagos N.V.
SRPT	Sarepta Therapeutics, Inc.
RCUS	Arcus Biosciences, Inc.
RXRX	Recursion Pharmaceuticals, Inc.
DNLI	Denali Therapeutics Inc.
BEAM	Beam Therapeutics Inc.
IBRX	ImmunityBio, Inc.
COGT	Cogent Biosciences, Inc.
LQDA	Liquidia Corporation